ADVERTISEMENT

Hospital isolates C. difficile carriers and rates drop

AT ASM MICROBE 2017

Long-term follow-up is ongoing, Dr. Longtin said. “We have more than 3 years of intervention. In the past year, our rate was 2.2 per 10,000 patient-days.”

Unanswered questions include the generalizability of the results “because we’re a very pro–infection control hospital,” he said. In addition, a formal cost-benefit analysis of this strategy would be worthwhile in the future.

Dr. Longtin is a consultant for AMG Medical and receives research support from Merck and BD Medical.